$HLSQ Balance Sheet | Understand Stock

$HLSQ

$0.21 -$0.05 (18.2%) Close

$HLSQ Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Unaudited Condensed Consolidated Interim Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Current Assets
Cash and cash equivalents
Restricted cash
Short term investments
Property and equipment, held for sale
Trade receivables
Other current assets
Total Current assets
Other assets
Non-current Assets
Other assets
Non-current restricted cash
Property and Equipment, Net
Intangible assets, net
In-process Research and development (“IPR&D”) assets and Goodwill
In-process Research and development (“IPR&D”) assets
Right Of Use asset arising from operating lease and deposits
Goodwill & intangible assets
In-process Research and development (“IPR&D”) asset
Funds in respect of employee rights upon terminations
Total Non-current assets

Total assets

Liabilities and Capital Deficiency
Current Liabilities
Trade accounts payable
Short term bank credit
Trade account payables
Contract liability
Other accounts payable
Balance due to Biomx Ltd
Loans payable - related parties
Contingent consideration
Promissory notes
Warrant liability issued as consideration for subsidiary acquisition
Current portion of lease liabilities
Other account payables
Current portion of long-term debt
Total current liabilities

Non-current Liabilities
Contract liability
Long term loans, net of current portion
Right Of Use liabilities arising from operating lease
Other liabilities
Private Placement Warrants
Severance pay liability
Warrants
Private Placement
Total warrants
Total non-current liabilities
Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of March 31, 2024 and December 31, 2023. Issued and outstanding- 256,887 as of March 31, 2024. No shares issued and outstanding as of December 31, 2023.
Total liabilities
Stockholders’ equity (deficit)
Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of June 30, 2026 and December 31, 2025. Issued and outstanding – 51,598 as of June 30, 2026 and 147,512 shares as of December 31, 2025.
Common stock, $0.0001 par value (“Common Stock”); Authorized - 750,000,000 shares as of June 30, 2026 and December 31, 2025. Issued and outstanding – 12,590,640 and 1,593,703 as of June 30, 2026 and December 31, 2025, respectively.
Receivables on account of shares
Additional paid-in capital
Accumulated deficit
Foreign currency translation adjustments
Total Company’s stockholders’ equity (deficit)
Non-controlling interests
Total Stockholders’ equity (deficit)
Total liabilities and Stockholders’ equity (deficiency)

Comments